Semaglutide Explained: How Ozempic, Wegovy, and Rybelsus Differ and Which Does What

Medically reviewed by the UTCardiothoracicSurgery.com editorial team | Published April 1, 2026

Disclaimer: This article is for educational purposes only and doesn't constitute medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Don't start, stop, or change any medication without consulting your doctor.

Three Brand Names, One Molecule: Understanding Semaglutide

Here's something that confuses almost everyone who starts researching GLP-1 weight loss medications: Ozempic, Wegovy, and Rybelsus all contain the exact same active ingredient — semaglutide. They're not different drugs. They're different brand names for the same molecule, manufactured by the same company (Novo Nordisk), but approved for different uses, at different doses, and in different formats.

Understanding these distinctions isn't just trivia — it directly affects what your insurance covers, what dose you'll take, how you'll take it, and whether your prescription is on-label or off-label. Let's walk through each one.

For the broader overview of how GLP-1 medications work and how semaglutide compares to tirzepatide, start with our complete GLP-1 guide.

Ozempic: The Diabetes Drug That Started the Weight Loss Conversation

FDA-approved indication: Type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established heart disease.

Format: Weekly subcutaneous injection (under the skin) using a prefilled pen.

Dosing: Starts at 0.25 mg weekly for the first 4 weeks, then increases to 0.5 mg. Can be further increased to 1 mg and eventually 2 mg based on blood sugar response and tolerability.

What you need to know: Ozempic was approved in 2017 for type 2 diabetes, not weight loss. But patients and their doctors noticed something striking — people were losing significant weight as a “side effect” of their diabetes medication. This observation, backed by clinical trial data showing substantial weight reduction, sparked the massive interest in semaglutide for weight management.

Today, Ozempic is widely prescribed off-label for weight loss in patients who don't have diabetes. Off-label prescribing is legal and common in medicine — it means using an FDA-approved drug for a purpose other than its approved indication. However, insurance coverage for off-label use can be limited, and the maximum dose (2 mg) is lower than the weight-loss-specific dose available with Wegovy (2.4 mg).

Ozempic also carries an FDA-approved indication for reducing cardiovascular events in adults with type 2 diabetes and established heart disease, which adds a meaningful benefit beyond blood sugar control. For our deep dive into the cardiovascular evidence, see our GLP-1 and heart health article.

Wegovy: The Same Molecule, Specifically for Weight Loss

FDA-approved indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Also approved for cardiovascular risk reduction in adults with established heart disease and overweight or obesity. Additionally approved for weight management in children aged 12 and older with obesity.

Format: Weekly subcutaneous injection using a prefilled pen, AND a daily oral tablet (launched in early 2026).

Dosing (injectable): Gradual titration starting at 0.25 mg weekly, increasing monthly through 0.5 mg, 1 mg, 1.7 mg, and reaching the target dose of 2.4 mg. The full titration takes approximately 16-20 weeks.

Dosing (oral tablet): Follows a separate titration schedule. Must be taken on an empty stomach with no more than 4 ounces of water, at least 30 minutes before eating, drinking, or taking other medications.

What you need to know: Wegovy is the FDA-approved weight loss version of semaglutide. The clinical evidence backing it comes from the STEP trial program, which demonstrated an average of 14.9% body weight loss over 68 weeks. Because it's specifically approved for weight management, insurance coverage for weight loss is generally better with Wegovy than with off-label Ozempic — though coverage still varies significantly by plan.

The big news in 2026 was the launch of the Wegovy oral tablet, making semaglutide the first GLP-1 available in both injectable and pill form for weight management. The OASIS 4 trial showed comparable weight loss results between the oral and injectable versions. We cover oral options in detail in our oral GLP-1 pills guide.

The cardiovascular approval for Wegovy was based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events — the same landmark study we discuss in our heart health article. This makes Wegovy the first weight loss medication ever to receive an FDA-approved cardiovascular benefit indication.

Rybelsus: The Daily Pill for Diabetes

FDA-approved indication: Type 2 diabetes management (improving blood sugar control).

Format: Daily oral tablet.

Dosing: Starts at 3 mg daily for 30 days, then increases to 7 mg daily. Can be increased to 14 mg if additional blood sugar control is needed.

What you need to know: Rybelsus was the first oral semaglutide product, approved in 2019 for type 2 diabetes. It's not FDA-approved for weight loss, and its doses (maxing out at 14 mg) are lower than the weight-loss-optimized oral Wegovy doses. Some doctors prescribe it off-label for weight management, but the evidence base for weight loss is stronger with Wegovy's higher doses.

Rybelsus shares the same absorption requirements as oral Wegovy — it must be taken on an empty stomach with minimal water, at least 30 minutes before eating or drinking anything else. This is because semaglutide is a peptide that gets broken down in the gut, so the absorption conditions need to be precisely controlled.

Quick Comparison Table: Ozempic vs. Wegovy vs. Rybelsus

Ozempic: Weekly injection. FDA-approved for diabetes + cardiovascular risk reduction. Max dose 2 mg. Often used off-label for weight loss. Insurance coverage typically better for diabetes indication.

Wegovy: Weekly injection OR daily oral tablet. FDA-approved for weight loss + cardiovascular risk reduction. Max injectable dose 2.4 mg. Specific weight loss approval may improve insurance access for weight management. First GLP-1 with both injectable and oral options for weight loss.

Rybelsus: Daily oral tablet. FDA-approved for diabetes only. Max dose 14 mg. Lowest weight-loss evidence of the three. Best suited for patients who need blood sugar control and prefer a pill over injection.

Off-Label Prescribing: What It Means and Why It Matters

When a doctor prescribes Ozempic for weight loss in a patient without diabetes, that's off-label prescribing. This is completely legal and extremely common across all fields of medicine — estimates suggest that about 20% of all prescriptions in the United States are written off-label.

The reason it matters for patients is primarily financial. Insurance companies are generally more willing to cover medications for their FDA-approved indications. If your doctor prescribes Ozempic for diabetes, your insurance is more likely to cover it than if the prescription is explicitly for weight loss. Some doctors navigate this by documenting the diabetes-related or cardiovascular-related rationale for prescribing, even when weight loss is the primary clinical goal.

For the full breakdown of eligibility, insurance strategies, and cost considerations, see our who qualifies guide and our cost and access guide.

Compounded Semaglutide: The Budget Alternative

With brand-name semaglutide costing $900-1,400 per month without insurance, a significant market for compounded semaglutide has developed — custom-prepared versions from compounding pharmacies at roughly $179-299 per month.

This is an area where you need to be well-informed before making decisions. Compounded semaglutide is not FDA-approved, hasn't been through clinical trials, and quality can vary between pharmacies. The FDA has raised specific concerns about salt forms (semaglutide acetate vs. semaglutide base) and additional ingredients that haven't been studied in combination with semaglutide.

We cover this complex topic — including what to look for, what to avoid, and how to evaluate your options — in our dedicated compounded vs. brand-name article.

Frequently Asked Questions

Can I switch from Ozempic to Wegovy (or vice versa)?

Yes, since they contain the same active ingredient. Your doctor will determine the equivalent dose and manage the transition. The main reasons for switching include changing from a diabetes indication to a weight loss indication (or the reverse), accessing higher doses (Wegovy goes up to 2.4 mg vs. Ozempic's 2 mg), or navigating insurance coverage changes.

Is one brand “better” than the others?

They all contain semaglutide, so the molecule itself is identical. The “best” choice depends on your clinical situation: what you're treating (diabetes vs. weight management), how you prefer to take medication (injection vs. pill), what your insurance covers, and what doses you need.

Does the Wegovy pill work as well as the injection?

The OASIS 4 clinical trial showed comparable weight loss between oral and injectable semaglutide. However, oral semaglutide has stricter dosing requirements — it must be taken daily on an empty stomach with minimal water. Compliance can be more challenging than a once-weekly injection for some patients. See our oral GLP-1 guide for the full analysis.

Why is semaglutide so expensive?

Semaglutide is a biologic peptide that requires complex manufacturing. Novo Nordisk holds the patents and has no generic competition yet. The pricing also reflects the R&D investment behind the extensive clinical trial program (STEP, SELECT, SUSTAIN, OASIS trials) that established safety and efficacy. See our cost guide for savings strategies.

For the comparison with tirzepatide (Mounjaro/Zepbound), which works through a different dual-hormone mechanism, read our head-to-head comparison.

This article will be updated as new FDA actions and clinical data become available. Last reviewed: April 1, 2026.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.